NIKKEI 225
38,286.89 +12.84 (+0.03%) HANG SENG
18,086.75 +323.72 (+1.82%) CRUDE OIL
79.45 +0.45 (+0.57%) GOLD FUTURES
2,328.10 +17.10 (+0.74%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,863.66 -2,160.14 (-4.50%)
Dr. Reddy's Laboratories Limited (DRREDDY.NS)
| Previous close | 6,204.30 |
| Open | 6,195.25 |
| Bid | 6,222.40 x 0 |
| Ask | 6,245.00 x 0 |
| Day's range | 6,195.25 - 6,245.05 |
| 52-week range | 4,384.05 - 6,505.90 |
| Volume | |
| Avg. volume | 361,051 |
| Market cap | 1.039T |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 19.92 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 40.00 (0.64%) |
| Ex-dividend date | 11 Jul 2023 |
| 1y target est | N/A |
- GlobeNewswire
Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
- Business Wire
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India, March 19, 2024--Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
- Business Wire
Dr. Reddy’s Q3 & 9M FY24 Financial Results
HYDERABAD, India, January 31, 2024--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2023.
